A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis

Kenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, Shigeki Saito, Kohshi Ohishi, Hiroshi Handa, Katsuto Takenaka, Prashanth Gopalakrishna, Taro Amagasaki, Kazuo Ito, Koichi Akashi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis. Ruxolitinib was well tolerated and effectively reduced splenomegaly and symptom burden in Asian patients with myelofibrosis in the Asian multinational, phase 2 Study A2202. We present a subset analysis of Japanese patients (n = 30) in Study A2202. At data cutoff, 22 patients were ongoing; 8 discontinued, mainly due to adverse events (n = 4). At week 24, 33 % of patients achieved ≥35 % reduction from baseline in spleen volume; 56.0 % achieved ≥50 % reduction from baseline in total symptom score, as measured by the 7-day Myelofibrosis Symptom Assessment Form v2.0. The most common adverse events were anemia (63 %), thrombocytopenia (40 %), nasopharyngitis (37 %), decreased platelet counts (30 %), and diarrhea (30 %). Dose reductions or interruptions due to hemoglobin decreases were more frequent in Japanese patients; no loss of efficacy and no discontinuations due to hematologic abnormalities were observed. Ruxolitinib was well tolerated in Japanese patients and provided substantial reductions in splenomegaly and myelofibrosis-related symptoms similar to those observed in the overall Asian population and phase 3 COMFORT studies.

Original languageEnglish
Pages (from-to)295-304
Number of pages10
JournalInternational Journal of Hematology
Volume101
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

Primary Myelofibrosis
Splenomegaly
Janus Kinase 1
Nasopharyngitis
Symptom Assessment
INCB018424
Platelet Count
Thrombocytopenia
Anemia
Diarrhea
Hemoglobins
Spleen
Survival
Population

Keywords

  • JAK inhibitor
  • Japan
  • Myelofibrosis
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology

Cite this

A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis : Japanese subset analysis. / Oritani, Kenji; Okamoto, Shinichiro; Tauchi, Tetsuzo; Saito, Shigeki; Ohishi, Kohshi; Handa, Hiroshi; Takenaka, Katsuto; Gopalakrishna, Prashanth; Amagasaki, Taro; Ito, Kazuo; Akashi, Koichi.

In: International Journal of Hematology, Vol. 101, No. 3, 2015, p. 295-304.

Research output: Contribution to journalArticle

Oritani, K, Okamoto, S, Tauchi, T, Saito, S, Ohishi, K, Handa, H, Takenaka, K, Gopalakrishna, P, Amagasaki, T, Ito, K & Akashi, K 2015, 'A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis', International Journal of Hematology, vol. 101, no. 3, pp. 295-304. https://doi.org/10.1007/s12185-015-1746-8
Oritani, Kenji ; Okamoto, Shinichiro ; Tauchi, Tetsuzo ; Saito, Shigeki ; Ohishi, Kohshi ; Handa, Hiroshi ; Takenaka, Katsuto ; Gopalakrishna, Prashanth ; Amagasaki, Taro ; Ito, Kazuo ; Akashi, Koichi. / A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis : Japanese subset analysis. In: International Journal of Hematology. 2015 ; Vol. 101, No. 3. pp. 295-304.
@article{b06d982960ad41aba92a64fe106e3078,
title = "A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis",
abstract = "Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis. Ruxolitinib was well tolerated and effectively reduced splenomegaly and symptom burden in Asian patients with myelofibrosis in the Asian multinational, phase 2 Study A2202. We present a subset analysis of Japanese patients (n = 30) in Study A2202. At data cutoff, 22 patients were ongoing; 8 discontinued, mainly due to adverse events (n = 4). At week 24, 33 {\%} of patients achieved ≥35 {\%} reduction from baseline in spleen volume; 56.0 {\%} achieved ≥50 {\%} reduction from baseline in total symptom score, as measured by the 7-day Myelofibrosis Symptom Assessment Form v2.0. The most common adverse events were anemia (63 {\%}), thrombocytopenia (40 {\%}), nasopharyngitis (37 {\%}), decreased platelet counts (30 {\%}), and diarrhea (30 {\%}). Dose reductions or interruptions due to hemoglobin decreases were more frequent in Japanese patients; no loss of efficacy and no discontinuations due to hematologic abnormalities were observed. Ruxolitinib was well tolerated in Japanese patients and provided substantial reductions in splenomegaly and myelofibrosis-related symptoms similar to those observed in the overall Asian population and phase 3 COMFORT studies.",
keywords = "JAK inhibitor, Japan, Myelofibrosis, Ruxolitinib",
author = "Kenji Oritani and Shinichiro Okamoto and Tetsuzo Tauchi and Shigeki Saito and Kohshi Ohishi and Hiroshi Handa and Katsuto Takenaka and Prashanth Gopalakrishna and Taro Amagasaki and Kazuo Ito and Koichi Akashi",
year = "2015",
doi = "10.1007/s12185-015-1746-8",
language = "English",
volume = "101",
pages = "295--304",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis

T2 - Japanese subset analysis

AU - Oritani, Kenji

AU - Okamoto, Shinichiro

AU - Tauchi, Tetsuzo

AU - Saito, Shigeki

AU - Ohishi, Kohshi

AU - Handa, Hiroshi

AU - Takenaka, Katsuto

AU - Gopalakrishna, Prashanth

AU - Amagasaki, Taro

AU - Ito, Kazuo

AU - Akashi, Koichi

PY - 2015

Y1 - 2015

N2 - Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis. Ruxolitinib was well tolerated and effectively reduced splenomegaly and symptom burden in Asian patients with myelofibrosis in the Asian multinational, phase 2 Study A2202. We present a subset analysis of Japanese patients (n = 30) in Study A2202. At data cutoff, 22 patients were ongoing; 8 discontinued, mainly due to adverse events (n = 4). At week 24, 33 % of patients achieved ≥35 % reduction from baseline in spleen volume; 56.0 % achieved ≥50 % reduction from baseline in total symptom score, as measured by the 7-day Myelofibrosis Symptom Assessment Form v2.0. The most common adverse events were anemia (63 %), thrombocytopenia (40 %), nasopharyngitis (37 %), decreased platelet counts (30 %), and diarrhea (30 %). Dose reductions or interruptions due to hemoglobin decreases were more frequent in Japanese patients; no loss of efficacy and no discontinuations due to hematologic abnormalities were observed. Ruxolitinib was well tolerated in Japanese patients and provided substantial reductions in splenomegaly and myelofibrosis-related symptoms similar to those observed in the overall Asian population and phase 3 COMFORT studies.

AB - Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis. Ruxolitinib was well tolerated and effectively reduced splenomegaly and symptom burden in Asian patients with myelofibrosis in the Asian multinational, phase 2 Study A2202. We present a subset analysis of Japanese patients (n = 30) in Study A2202. At data cutoff, 22 patients were ongoing; 8 discontinued, mainly due to adverse events (n = 4). At week 24, 33 % of patients achieved ≥35 % reduction from baseline in spleen volume; 56.0 % achieved ≥50 % reduction from baseline in total symptom score, as measured by the 7-day Myelofibrosis Symptom Assessment Form v2.0. The most common adverse events were anemia (63 %), thrombocytopenia (40 %), nasopharyngitis (37 %), decreased platelet counts (30 %), and diarrhea (30 %). Dose reductions or interruptions due to hemoglobin decreases were more frequent in Japanese patients; no loss of efficacy and no discontinuations due to hematologic abnormalities were observed. Ruxolitinib was well tolerated in Japanese patients and provided substantial reductions in splenomegaly and myelofibrosis-related symptoms similar to those observed in the overall Asian population and phase 3 COMFORT studies.

KW - JAK inhibitor

KW - Japan

KW - Myelofibrosis

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=84925538391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925538391&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1746-8

DO - 10.1007/s12185-015-1746-8

M3 - Article

C2 - 25638222

AN - SCOPUS:84925538391

VL - 101

SP - 295

EP - 304

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -